As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Mineralys Therapeutics Inc. The largest reported stake is Catalys Pacific Fund, LP's, at 10.1%. 8 filings are on record since August 14, 2025 (Schedule 13G/A, February 13, 2026).
Sell to companies like Mineralys Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 4,461,164 · Shared voting: 0 · Sole dispositive: 4,461,689 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-06
- · Reporting person: Catalys Pacific Fund, LP · Sole voting: 0 · Shared voting: 8,002,738 · Sole dispositive: 0 · Shared dispositive: 8,002,738 · SCHEDULE 13G/A, 2026-02-13
- · Holder: Fmr LLC · Percent: 6.3% · SCHEDULE 13G
- · Reporting person: BlackRock, Inc. · Sole voting: 4,041,593 · Shared voting: 0 · Sole dispositive: 4,113,657 · Shared dispositive: 0 · SCHEDULE 13G, 2026-01-21
- · Holder: RA Capital Management, L.P. · Percent: 9.9% · SCHEDULE 13D/A
Mineralys Therapeutics Inc has 8 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Catalys Pacific Fund, LP | 10.1% | 8,002,738 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| RA Capital Management, L.P. | 9.9% | 7,796,433 | SCHEDULE 13D/A, 2025-09-08 | 2025-09-04 |
| Samsara BioCapital, L.P. | 8.2% | 5,674,916 | SCHEDULE 13D/A, 2025-09-08 | 2025-09-04 |
| BlackRock, Inc. | 5.2% | 4,113,657 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
| Fmr LLC | 5.1% | 4,461,689 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| Andera Partners | 4.2% | 2,765,976 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Mineralys Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Mineralys Therapeutics Inc and the records around it.
Mineralys Therapeutics Inc elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Andera Partners also filed stake reports on 2 other companies: Inventiva S.A. (Oct 2026), EVOMMUNE, INC. (Aug 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Mineralys Therapeutics Inc
Get an email when Mineralys Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mineralys Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mineralys Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mineralys Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Catalys Pacific Fund, LP | 0 | 8,002,738 | 0 | 8,002,738 | SCHEDULE 13G/A, 2026-02-13 |
| Catalys Pacific Fund GP, LP | 0 | 8,002,738 | 0 | 8,002,738 | SCHEDULE 13G/A, 2026-02-13 |
| Catalys Pacific, LLC | 0 | 8,002,738 | 0 | 8,002,738 | SCHEDULE 13G/A, 2026-02-13 |
| Brian Taylor Slingsby | 0 | 8,002,738 | 0 | 8,002,738 | SCHEDULE 13G/A, 2026-02-13 |
| BlackRock, Inc. | 4,041,593 | 0 | 4,113,657 | 0 | SCHEDULE 13G, 2026-01-21 |
| Fmr LLC | 4,461,164 | 0 | 4,461,689 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 4,461,689 | 0 | SCHEDULE 13G/A, 2026-08-06 |
The latest filing identifies Mineralys Therapeutics Inc by CUSIP 603170101 and gives its principal executive office as 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR, PA 19087 (SCHEDULE 13G/A, 2026-08-06).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Catalys Pacific Fund, LP | 13.5% | SCHEDULE 13G/A |
| 2025-08-14 | Andera Partners | 4.2% | SCHEDULE 13G/A |
| 2025-09-08 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13D/A |
| 2025-09-08 | Samsara BioCapital, L.P. | 8.2% | SCHEDULE 13D/A |
| 2026-01-21 | BlackRock, Inc. | 5.2% | SCHEDULE 13G |
| 2026-02-05 | Fmr LLC | 6.3% | SCHEDULE 13G |
| 2026-02-13 | Catalys Pacific Fund, LP | 10.1% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 5.1% | SCHEDULE 13G/A |
Questions about who owns Mineralys Therapeutics Inc
Who owns Mineralys Therapeutics Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Mineralys Therapeutics Inc: Catalys Pacific Fund, LP (10.1%, Schedule 13G/A, filed 2026-02-13), RA Capital Management, L.P. (9.9%, Schedule 13D/A, filed 2025-09-08), Samsara BioCapital, L.P. (8.2%, Schedule 13D/A, filed 2025-09-08), BlackRock, Inc. (5.2%, Schedule 13G, filed 2026-01-21) and Fmr LLC (5.1%, Schedule 13G/A, filed 2026-08-06).
Who are the largest shareholders of Mineralys Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Mineralys Therapeutics Inc on this page are Catalys Pacific Fund, LP (10.1%), RA Capital Management, L.P. (9.9%) and Samsara BioCapital, L.P. (8.2%).
When did Catalys Pacific Fund, LP buy into Mineralys Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Catalys Pacific Fund, LP on this page is the Schedule 13G/A, filed 2025-08-14, reporting 13.5%; its latest, Schedule 13G/A filed 2026-02-13, reports 10.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Mineralys Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| October 19, 2026 | Leadership change: Kristine Peterson appointed, Director, and 1 more | — | Leadership changes | Source |
| August 11, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Mineralys Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.